Share on StockTwits

Achillion Pharmaceuticals (NASDAQ:ACHN) CEO Milind Deshpande sold 216,624 shares of the company’s stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $10.00, for a total transaction of $2,166,240.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

ACHN has been the subject of a number of recent research reports. Analysts at Deutsche Bank upgraded shares of Achillion Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday. They now have a $17.00 price target on the stock, up previously from $6.00. Separately, analysts at Maxim Group reiterated a “buy” rating on shares of Achillion Pharmaceuticals in a research note on Friday. Finally, analysts at FBR Capital Markets initiated coverage on shares of Achillion Pharmaceuticals in a research note on Friday. They set an “outperform” rating and a $12.00 price target on the stock. One analyst has rated the stock with a sell rating, four have issued a hold rating and seven have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $8.90.

Achillion Pharmaceuticals (NASDAQ:ACHN) traded up 3.46% during mid-day trading on Tuesday, hitting $9.87. 7,249,328 shares of the company’s stock traded hands. Achillion Pharmaceuticals has a 52-week low of $2.26 and a 52-week high of $10.10. The stock has a 50-day moving average of $7.43 and a 200-day moving average of $4.69. The company’s market cap is $965.2 million.

Achillion Pharmaceuticals (NASDAQ:ACHN) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.16) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.18) by $0.02. On average, analysts predict that Achillion Pharmaceuticals will post $-0.69 earnings per share for the current fiscal year.

Achillion Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.